Comparative Pharmacology
Head-to-head clinical analysis: ORUDIS KT versus RELAFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORUDIS KT versus RELAFEN.
ORUDIS KT vs RELAFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nabumetone is a nonacidic nonsteroidal anti-inflammatory drug (NSAID) that is a prodrug, rapidly metabolized to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which inhibits cyclooxygenase (COX) and thereby prostaglandin synthesis.
50 mg orally three times daily or 75 mg orally twice daily; maximum 300 mg/day.
1000 mg orally once daily, or 500 mg twice daily. Maximum dose 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (increased in elderly and renal impairment, up to 12 hours).
Terminal elimination half-life approximately 24 hours (range 20-30 hours), allowing once-daily dosing.
Renal (approximately 60-80% as metabolites, <10% unchanged); biliary/fecal (approximately 20-35%).
Primarily renal (90% as metabolites, ~5% unchanged); biliary/fecal minor (<5%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)